


ManNAc for Focal Segmental Glomerulosclerosis Now Enrolling!



The NIH Clinical Center is recruiting adults (≥ 18 years) with biopsy-confirmed primary focal segmental glomerulosclerosis (FSGS) in a single-site, open-label Phase 2 clinical trial evaluating the safety and efficacy of the investigational drug N-acetylmannosamine (ManNAc) for reducing proteinuria. The research study is led by Dr. William Gahl (NHGRI), in collaboration with investigators from NIDDK.

Participants will need to make two inpatient visits to the NIH (each lasting 2-3 overnights) and four outpatient NIH visits (lasting a few hours each). ManNAc is taken orally as a powder dissolved in water twice daily. The NIH will assist with lodging and travel. Compensation up to \$2,000 over the course of the study will be provided.

NIH Clinical Center Office of Patient Recruitment
833-JOIN-NIH
TTY users dial 7-1-1
kidneymannac@mail.nih.gov
NIH research study #002066-HG

The NIH Clinical Center, America's Research Hospital,
is located in Bethesda, MD.

